The control of diseases such as ELA or the application of more specific drugs, through nanotechnology, are some of the research lines of this center.
Cabimer aspires to continue growing after a decade marked by the crisis: Cabimer aspires to continue growing after a decade marked by the crisis
The Andalusian Center for Molecular Biology and Regenerative Medicine (Cabimer) has been investigating pathologies such as diabetes, cancer, rare diseases, pigmentary renitosis or multiple sclerosis for ten years.He was born as a reference in the investigation of the stem cells, has managed to overcome the crisis and now intends to continue growing after the break in the number of researchers five years ago.
In Cabimer, located on the island of Cartuja, they investigate how different diseases and their possible 190 workers from 19 groups behave.It was born in 2006 and shortly after the crisis that this center has managed to overcome was unleashed, according to the director of the center, Andrés Aguilera, who sees a greater financing.In 2011 there was a break in the number of researchers that remains, but now aspire to expand the figure to 230.
Ten years after taking the first steps, greater applicability in the health system is now raised among their challenges and foster its most international aspect.One of his diabetes projects has achieved half a million dollars from an American Foundation.
It is working on 62 research projects, 34 patents have achieved and six clinical trials have been carried out.In the Macarena Hospital, for example, an essay on the diabetic foot is being carried out to reduce the impact of diabetes.It is working on neurodegenerative diseases, including amyotrophic lateral sclerosis, for which there is no effective therapeutic response.Interesting results are being obtained, which are now in patent phase, according to the researcher, David del Pozo, who launches a message of hope.
His laboratory also works with nanotechnology, matter of nanometric scale, which will allow more and more in the coming years the drugs to be dispensed more specifically with less adverse effects.These are semi-intelligent formulas, which travel inside the body, detect a problem and dispense a substance to treat it.
